Hostname: page-component-848d4c4894-pftt2 Total loading time: 0 Render date: 2024-05-05T00:35:38.731Z Has data issue: false hasContentIssue false
  • English
  • Français

Modelling the cost-effectiveness of pharmacotherapy compared with cognitive–behavioural therapy and combination therapy for the treatment of moderate to severe depression in the UK

Published online by Cambridge University Press:  04 June 2015

L. Koeser ,
V. Donisi ,
D. P. Goldberg  and
P. McCrone
L. Koeser*
Affiliation:
Institute of Psychiatry, King's College London, London, UK
V. Donisi
Affiliation:
Department of Public Health and Community Medicine, Section of Psychiatry, University of Verona, Verona, Italy
D. P. Goldberg
Affiliation:
Institute of Psychiatry, King's College London, London, UK
P. McCrone
Affiliation:
Institute of Psychiatry, King's College London, London, UK
*
*Address for correspondence: L. Koeser, Health Service and Population Research Department, Institute of Psychiatry, King's College London, Box P024, De Crespigny Park, London SE5 8AF, UK. (Email: leonardo.koeser@kcl.ac.uk)
Get access Rights & Permissions [Opens in a new window]

Abstract

Background.

The National Institute of Health and Care Excellence (NICE) in England and Wales recommends the combination of pharmacotherapy and psychotherapy for the treatment of moderate to severe depression. However, the cost-effectiveness analysis on which these recommendations are based has not included psychotherapy as monotherapy as a potential option. For this reason, we aimed to update, augment and refine the existing economic evaluation.

Method.

We constructed a decision analytic model with a 27-month time horizon. We compared pharmacotherapy with cognitive–behavioural therapy (CBT) and combination treatment for moderate to severe depression in secondary care from a healthcare service perspective. We reviewed the literature to identify relevant evidence and, where possible, synthesized evidence from clinical trials in a meta-analysis to inform model parameters.

Results.

The model suggested that CBT as monotherapy was most likely to be the most cost-effective treatment option above a threshold of £22 000 per quality-adjusted life year (QALY). It dominated combination treatment and had an incremental cost-effectiveness ratio of £20 039 per QALY compared with pharmacotherapy. There was significant decision uncertainty in the probabilistic and deterministic sensitivity analyses.

Conclusions.

Contrary to previous NICE guidance, the results indicated that even for those patients for whom pharmacotherapy is acceptable, CBT as monotherapy may be a cost-effective treatment option. However, this conclusion was based on a limited evidence base, particularly for combination treatment. In addition, this evidence cannot easily be transferred to a primary care setting.

Keywords

Antidepressantscognitive-behavioural therapycost-effectiveness analysisdepressionNational Institute of Health and Care Excellence
Type
Original Articles
Information
Psychological Medicine , Volume 45 , Issue 14 , October 2015 , pp. 3019 - 3031
Copyright
Copyright © Cambridge University Press 2015 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Afzali, HHA, Karnon, J, Gray, J (2012 a). A critical review of model-based economic studies of depression. Pharmacoeconomics 30, 461–482.Google Scholar
Afzali, HHA, Karnon, J, Gray, J (2012 b). A proposed model for economic evaluations of major depressive disorder. European Journal of Health Economics 13, 501–510.Google Scholar
American Psychiatric Association (2000). Handbook of Psychiatric Measures. American Psychiatric Publishing, Inc.: Washington, DC.Google Scholar
Baio, G (2012). Bayesian Methods in Health Economics. Chapman and Hall/CRC Press: Boca Raton, FL. CrossRefGoogle Scholar
Borenstein, M, Hedges, LV, Higgins, JPT, Rothstein, HR (2009). Introduction to Meta-Analysis. Wiley: Chichester.CrossRefGoogle Scholar
Clark, DM (2011). Implementing NICE guidelines for the psychological treatment of depression and anxiety disorders: the IAPT experience. International Review of Psychiatry 23, 318–327.Google Scholar
Cuijpers, P, Reynolds, CF, Donker, T, Li, J, Andersson, G, Beekman, A (2012). Personalized treatment of adult depression: medication, psychotherapy, or both? A systematic review. Depression and Anxiety 29, 855–864.CrossRefGoogle ScholarPubMed
Cuijpers, P, van Straten, A, Warmerdam, L, Andersson, G (2008). Psychological treatment of depression: a meta-analytic database of randomized studies. BMC Psychiatry 8, 36.Google Scholar
Curtis, L (2012). Unit Costs of Health and Social Care 2012. Personal Social Services Research Unit: Canterbury.Google Scholar
Department of Health (2012). IAPT three-year report – the first million patients. Department of Health: London.Google Scholar
Dias, S, Sutton, AJ, Ades, AE, Welton, NJ (2013 a). Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Medical Decision Making 33, 607–617.CrossRefGoogle ScholarPubMed
Dias, S, Sutton, AJ, Welton, NJ, Ades, AE (2013 b). Evidence synthesis for decision making 3: heterogeneity – subgroups, meta-regression, bias, and bias-adjustment. Medical Decision Making 33, 618–640.Google Scholar
Dias, S, Welton, NJ, Sutton, AJ, Ades, AE (2013 c). Evidence synthesis for decision making 5: the baseline natural history model. Medical Decision Making 33, 657–670.Google Scholar
Driessen, E, Hollon, SD (2010). Cognitive behavioral therapy for mood disorders: efficacy, moderators and mediators. Psychiatric Clinics of North America 33, 537–555.CrossRefGoogle ScholarPubMed
Fenwick, E, Byford, S (2005). A guide to cost-effectiveness acceptability curves. British Journal of Psychiatry 187, 106–108.Google Scholar
Fountoulakis, KN, Samara, MT, Siamouli, M (2014). Burning issues in the meta-analysis of pharmaceutical trials for depression. Journal of Psychopharmacology 28, 106–117.CrossRefGoogle ScholarPubMed
Fournier, JC, DeRubeis, RJ, Amsterdam, J, Shelton, RC, Hollon, SD (2015). Gains in employment status following antidepressant medication or cognitive therapy for depression. British Journal of Psychiatry 206, 332–338.Google Scholar
Gelman, A, Jakulin, A, Pittau, MG, Su, Y-S (2008). A weakly informative default prior distribution for logistic and other regression models. Annals of Applied Statistics 2, 1360–1383.Google Scholar
Grutters, JC, van Asselt, MA, Chalkidou, K, Joore, M (2015). Healthy decisions: towards uncertainty tolerance in healthcare policy. Pharmacoeconomics 33, 1–4.Google Scholar
Gyani, A, Pumphrey, N, Parker, H, Shafran, R, Rose, S (2012). Investigating the use of NICE guidelines and IAPT services in the treatment of depression. Mental Health in Family Medicine 9, 149–160.Google Scholar
Haycox, A (2013). How much should the NHS pay for a QALY? Pharmacoeconomics 31, 357–359.Google Scholar
Higgins, JP, Green, S (2008). Cochrane Handbook for Systematic Reviews of Interventions. Wiley Online Library: Chichester.CrossRefGoogle Scholar
Hollinghurst, S, Carroll, FE, Abel, A, Campbell, J, Garland, A, Jerrom, B, Kessler, D, Kuyken, W, Morrison, J, Ridgway, N, Thomas, L, Turner, K, Williams, C, Peters, TJ, Lewis, G, Wiles, N (2014). Cost-effectiveness of cognitive–behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: economic evaluation of the CoBalT Trial. British Journal of Psychiatry 204, 69–76.Google Scholar
Ilyas, S, Moncrieff, J (2012). Trends in prescriptions and costs of drugs for mental disorders in England, 1998–2010. British Journal of Psychiatry 200, 393–398.Google Scholar
Jarrett, RB, Kraft, D, Schaffer, M, Witt-Browder, A, Risser, R, Atkins, DH, Doyle, J (2000). Reducing relapse in depressed outpatients with atypical features: a pilot study. Psychother Psychosom 69, 232–239.Google Scholar
Joint Formulary Committee (2013). British National Formulary, 66th edn. BMJ Group and Pharmaceutical Press: London.Google Scholar
Keller, MB, McCullough, JP, Klein, DN, Arnow, B, Dunner, DL, Gelenberg, AJ, Markowitz, JC, Nemeroff, CB, Russell, JM, Thase, ME, Trivedi, MH, Blalock, JA, Borian, FE, Jody, DN, DeBattista, C, Koran, LM, Schatzberg, AF, Fawcett, J, Hirschfeld, RMA, Keitner, G, Miller, I, Kocsis, JH, Kornstein, SG, Manber, R, Ninan, PT, Rothbaum, B, Rush, AJ, Vivian, D, Zajecka, J (2000). A comparison of nefazodone, the cognitive behavioral–analysis system of psychotherapy, and their combination for the treatment of chronic depression. New England Journal of Medicine 342, 1462–1470.CrossRefGoogle ScholarPubMed
Kendrick, T, Chatwin, J, Dowrick, C, Tylee, A, Morriss, R, Peveler, R, Leese, M, McCrone, P, Harris, T, Moore, M, Byng, R, Brown, G, Barthel, S, Mander, H, Ring, A, Kelly, V, Wallace, V, Gabbay, M, Craig, T, Mann, A (2009). Randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care: the THREAD (THREshold for AntiDepressant response) study. Health Technol Assess 13, iiix2013;iv, ix-xi, 1–159.CrossRefGoogle ScholarPubMed
Kuyken, W, Byford, S, Taylor, RS, Watkins, E, Holden, E, White, K, Barrett, B, Byng, R, Evans, A, Mullan, E, Teasdale, JD (2008). Mindfulness-based cognitive therapy to prevent relapse in recurrent depression. J Consult Clin Psychol 76, 966–978.Google Scholar
Malek, MH (2000). Implementing QALYs. Hayward Medical Communications: London.Google Scholar
McCrone, P, Dhanasiri, S, Patel, A, Knapp, M, Lawton-Smith, S (2008). Paying the Price: the Cost of Mental Health Care in England to 2026. King's Fund: London.Google Scholar
Moore, M, Yuen, HM, Dunn, N, Mullee, MA, Maskell, J, Kendrick, T (2009). Explaining the rise in antidepressant prescribing: a descriptive study using the general practice research database. BMJ 339, b3999.Google Scholar
National Institute of Health and Care Excellence (2009). Depression: the NICE guideline on the treatment and management of depression – updated edition. In National Clinical Practice Guideline 90 (ed. National Collaborating Centre for Mental Health). The British Psychological Society and The Royal College of Psychiatrists: London.Google Scholar
National Institute of Health and Care Excellence (2013). Guide to the Methods of Technology Appraisal 2013. National Institute for Health and Care Excellence: London.Google Scholar
National Institute of Health and Care Excellence (2014). Value Based Assessment of Health Technologies. National Institute for Health and Care Excellence: London.Google Scholar
Radhakrishnan, M, Hammond, G, Jones, PB, Watson, A, McMillan-Shields, F, Lafortune, L (2013). Cost of Improving Access to Psychological Therapies (IAPT) programme: an analysis of cost of session, treatment and recovery in selected primary care trusts in the East of England region. Behaviour Research and Therapy 51, 37–45.Google Scholar
Riley, RD, Higgins, JPT, Deeks, JJ (2011). Interpretation of random effects meta-analyses. BMJ 342, d549.Google Scholar
Sado, M, Knapp, M, Yamauchi, K, Fujisawa, D, So, M, Nakagawa, A, Kikuchi, T, Ono, Y (2009). Cost-effectiveness of combination therapy versus antidepressant therapy for management of depression in Japan. Australian and New Zealand Journal of Psychiatry 43, 539–547.Google Scholar
Sculpher, M (2001). The role and estimation of productivity costs in economic evaluation. In Economic Evaluation in Health Care: Merging Theory with Practice (ed. Drummond, M and McGuire, A), pp. 94–112. Oxford University Press: Oxford.Google Scholar
Simon, GE, Perlis, RH (2010). Personalized medicine for depression: can we match patients with treatments? American Journal of Psychiatry 167, 1445–1455.Google Scholar
Simon, J, Pilling, S, Burbeck, R, Goldberg, D (2006). Treatment options in moderate and severe depression: decision analysis supporting a clinical guideline. British Journal of Psychiatry 189, 494–501.Google Scholar
Simons, AD, Murphy, GE, Levine, JL, Wetzel, RD (1986). Cognitive therapy and pharmacotherapy for depression. Sustained improvement over one year. Archives of General Psychiatry 43, 43–48.CrossRefGoogle ScholarPubMed
Turner, RM, Davey, J, Clarke, MJ, Thompson, SG, Higgins, JP (2012). Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. International Journal of Epidemiology 41, 818–827.CrossRefGoogle ScholarPubMed
van der Lem, R, van der Wee, NJA, van Veen, T, Zitman, FG (2012). Efficacy versus effectiveness: a direct comparison of the outcome of treatment for mild to moderate depression in randomized controlled trials and daily practice. Psychotherapy and Psychosomatics 81, 226–234.CrossRefGoogle ScholarPubMed
van Schaik, DJF, Klijn, AFJ, van Hout, HPJ, van Marwijk, HWJ, Beekman, ATF, de Haan, M, van Dyck, R (2004). Patients’ preferences in the treatment of depressive disorder in primary care. General Hospital Psychiatry 26, 184–189.Google Scholar
Wallace, ML, Frank, E, Kraemer, HC (2013). A novel approach for developing and interpreting treatment moderator profiles in randomized clinical trials. JAMA Psychiatry 70, 1241–1247.Google Scholar
Supplementary material: File

Koeser supplementary material

Appendices S1-S4

Download Koeser supplementary material(File)
File 493.1 KB